![1]()
News
Ticagrelor monotherapy tops DAPT for high-risk PCI patients
September 29, 2019
SAN FRANCISCO – TWILIGHT findings support move to shorter DAPT.
![1]()
News
Apixaban prevents clots with cancer
September 27, 2019
Does apixaban therapy decrease venous thromboembolism (VTE) in ambulatory patients with cancer at intermediate to high risk who are starting chemotherapy?
![1]()
News
Reversal agents for direct-acting oral anticoagulants
September 20, 2019
DOACs are increasingly prescribed for anticoagulation, thanks to its multiple advantages.
![1]()
News
Older IBD patients are most at risk of postdischarge VTE
September 10, 2019
Readmission for venous thromboembolism in patients with inflammatory bowel diseases most often occurs within 60 days of discharge.
![1]()
News
Use of a CDSS increases safe outpatient management of low-risk PE patients
September 5, 2019
Does the use of an electronic clinical decision support system (CDSS) increase the number of low-risk patients with acute pulmonary embolism (PE) discharged from the ED without increasing adverse events?
![1]()
News
Standardized communication may prevent anticoagulant adverse drug events
September 2, 2019
What information is needed on discharge to reduce anticoagulant adverse drug events (ADEs)?
![1]()
News
POP AGE shakes up DAPT in elderly
September 1, 2019
PARIS – Clopidogrel hailed as P2Y12 inhibitor of choice in older patients with non-ST-elevation ACS.
![1]()
News
Anticoagulant therapy for AFib in patients with end-stage renal disease
August 23, 2019
Apixaban may be safer than warfarin for patients who have ESRD and who plan for anticoagulation because of AFib.
News
Post-TAVR anticoagulation alone fails to cut stroke risk in AFib
August 19, 2019
By contrast, antiplatelet therapy linked to reduced risk of stroke, whether or not oral anticoagulation was used in this PARTNER II substudy.
![1]()
News
Shorter vs. longer DAPT following coronary stent placement
July 22, 2019
Is 6 months of dual antiplatelet therapy (DAPT) therapy noninferior to 12 months, following ST-elevation myocardial infarction (STEMI) with placement of second-generation drug-eluting stents?
